| 1 |
34929424 | Effects of chemotherapy on contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers: A nationwide cohort study. | 2022 Feb |
2 |
| 2 |
32720318 | Impact of the addition of carboplatin to anthracycline-taxane-based neoadjuvant chemotherapy on survival in BRCA1/2-mutated triple-negative breast cancer. | 2021 Feb 15 |
4 |
| 3 |
34454564 | Cytotoxic and targeted therapy for BRCA1/2-driven cancers. | 2021 Aug 28 |
1 |
| 4 |
33505905 | Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer. | 2020 |
2 |
| 5 |
28929593 | Efficacy of anthracycline/taxane-based neo-adjuvant chemotherapy on triple-negative breast cancer in BRCA1/BRCA2 mutation carriers. | 2018 May |
1 |
| 6 |
29047188 | Predictive value of BRCA1/2 mRNA expression for response to neoadjuvant chemotherapy in BRCA-negative breast cancers. | 2018 Jan |
4 |
| 7 |
29791287 | BRCA1/2 Mutations and Bevacizumab in the Neoadjuvant Treatment of Breast Cancer: Response and Prognosis Results in Patients With Triple-Negative Breast Cancer From the GeparQuinto Study. | 2018 Aug 1 |
2 |
| 8 |
29867226 | BRCA1/2 testing: therapeutic implications for breast cancer management. | 2018 Jul |
1 |
| 9 |
28066861 | The incidence of cardiomyopathy in BRCA1 and BRCA2 mutation carriers after anthracycline-based adjuvant chemotherapy. | 2017 Feb |
2 |
| 10 |
28157161 | An Exploratory Study to Determine Whether BRCA1 and BRCA2 Mutation Carriers Have Higher Risk of Cardiac Toxicity. | 2017 Feb 2 |
1 |
| 11 |
26749359 | Cardiac function in BRCA1/2 mutation carriers with history of breast cancer treated with anthracyclines. | 2016 Jan |
5 |
| 12 |
26918222 | A Case of Metaplastic Breast Cancer with Prolonged Response to Single Agent Liposomal Doxorubicin. | 2016 Jan 11 |
1 |
| 13 |
25480878 | Prevalence of BRCA1 mutations and responses to neoadjuvant chemotherapy among BRCA1 carriers and non-carriers with triple-negative breast cancer. | 2015 Mar |
3 |
| 14 |
25414026 | Breast cancer sensitivity to neoadjuvant therapy in BRCA1 and CHEK2 mutation carriers and non-carriers. | 2014 Dec |
1 |
| 15 |
24026861 | BRCA1 promoter methylation is a marker of better response to anthracycline-based therapy in sporadic TNBC. | 2013 Sep |
5 |
| 16 |
24217135 | The influence of BRCA1/BRCA2 mutations on toxicity related to chemotherapy and radiotherapy in early breast cancer patients. | 2013 |
1 |
| 17 |
22791366 | Systemic therapy options in BRCA mutation-associated breast cancer. | 2012 Sep |
1 |
| 18 |
21135055 | An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients. | 2011 Jul |
1 |
| 19 |
20209131 | The prognostic value of BRCA1 mRNA expression levels following neoadjuvant chemotherapy in breast cancer. | 2010 Mar 3 |
1 |
| 20 |
20582464 | DNA repair signature is associated with anthracycline response in triple negative breast cancer patients. | 2010 Aug |
1 |
| 21 |
18815879 | Metaplastic breast carcinomas are basal-like breast cancers: a genomic profiling analysis. | 2009 Sep |
1 |
| 22 |
19615284 | [Correlation of BRCA1 and APC aberrant methylation with the response to anthracycline-based neoadjuvant chemotherapy in primary breast cancer]. | 2009 Apr |
5 |
| 23 |
18946749 | Basal-like subtype and BRCA1 dysfunction in breast cancers. | 2008 Oct |
1 |
| 24 |
12611456 | Increased expression of BRCA1 mRNA predicts favorable response to anthracycline-containing chemotherapy in breast cancers. | 2003 Mar |
2 |